NovaUCD-based medtech OncoAssure has announced the launch of its OncoAssure Prostate Test in the US market, as well as plans to hold an investment round last year.
The next-generation prognostic test is designed to support clinical decision-making for men diagnosed with localised prostate cancer, and helps to assess the risk of aggressive disease and disease recurrence.